title: [Clinical evaluation of intramuscular imipenem/cilastatin sodium in surgical infections].
abstract: A multi-center clinical study was carried out at the first Department of Surgery, Okayama University Medical School and its affiliated institutions to evaluate the efficacy and safety profiles of intramuscular imipenem/cilastatin sodium (IPM/CS) in surgical infections, which were mainly biliary tract infections and peritonitis. The following results were obtained: 1. The efficacy rate was 72.0% in a total of 25 evaluable patients and 81.8% in patients with cholecystitis. 2. The efficacy rates in patients with and without underlying diseases were 70.0% and 73.3%, respectively, and they were 71.4% in patients with mild or moderate infections and 75.0% in patients with severe infections. 3. Bacteriologically, the eradication rate was 100% for Gram-positive bacteria and 62.5% for Gram-negative bacteria, with an overall eradication rate of 78.6%. The eradication rate for monomicrobial infections was 71.4% and that for polymicrobial infections was 100%. 4. Out of 25 patients, one developed diarrhea as a drug-related adverse reaction, and laboratory abnormalities attributable to the treatment were observed in 5 patients. None of them was serious, however. 5. The overall usefulness rate was 60.0%, and the usefulness for cholecystitis (72.7%) was superior to that for cholangitis (33.3%).
authors.affiliation: Department of Surgery, Iwakuni National Hospital.
authors.forename: E
authors.initials: E
authors.lastname: Konaga
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Orita
authors.forename: S
authors.initials: S
authors.lastname: Fuchimoto
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Kitagawa
authors.forename: N
authors.initials: N
authors.lastname: Tokuda
authors.forename: H
authors.initials: H
authors.lastname: Kimura
authors.forename: F
authors.initials: F
authors.lastname: Hamada
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiyama
mesh_terms: D000328:Adult; D000368:Aged; D002761:Cholangitis / Q000188:drug therapy*; D015377:Cilastatin / Q000008:administration & dosage* / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage* / Q000627:therapeutic use; D007273:Injections, Intramuscular; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy*; D011183:Postoperative Complications / Q000188:drug therapy*
chemical_list: D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination